Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
2015-08-03
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle
formulation and cisplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to
grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances
to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Paclitaxel
albumin-stabilized nanoparticle formulation may make tumor cells more sensitive to radiation
therapy. Giving radiation therapy and paclitaxel albumin-stabilized nanoparticle formulation
together with cisplatin and cetuximab may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel
albumin-stabilized nanoparticle formulation when given together with cisplatin, cetuximab,
and radiation therapy to see how well they work in treating patients with locally advanced
stage III or stage IV head and neck cancer.